<DOC>
	<DOCNO>NCT00821652</DOCNO>
	<brief_summary>The study design see course injection contain NY-ESO-1 protein ( tumor antigen , marker express tumor ) ; combination immune stimulant ( adjuvant ) Montanide , without resiquimod ( another adjuvant ) well tolerate safe patient surgically resect Stage IIB , IIC , Stage III Stage IV ( AJCC criterion ) melanoma , tumor express NY-ESO-1 . In addition , study design see patient 's body 's defense ( immune ) system boost ( strengthen ) vaccine addition resiquimod vaccine make likely .</brief_summary>
	<brief_title>Randomized , Double Blind , Placebo-controlled Topical Resiquimod Adjuvant NY-ESO-1 Protein Vaccination</brief_title>
	<detailed_description>There publish data application topical resiquimod combination antigen Montanide , therefore , study include 2-part design Part I represent dose-escalation part topical resiquimod open-label fashion . Part II represent randomize part . In Part I , 2 cohort plan : If dose-limiting toxicity ( DLT ) occur day 8 last vaccination cycle last patient enrol first cohort , 3 additional patient ( cohort 2 ) enrol . If DLT occur day 8 last vaccination cycle last patient enrol second cohort Part I , trial proceed Part II patient randomize .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>Inclusion Criteria Patients eligible enrollment fulfill follow criterion : 1 . Histological diagnosis surgically resect Stage IIB , IIC , Stage III Stage IV ( AJCC criterion ) melanoma independent NYESO1 expression tumor biopsy 2 . At least 4 week since surgery prior first dose study agent . 3 . Laboratory value within follow limit : Hemoglobin &gt; 10.0 g/dL Neutrophil count &gt; 1.5 x l09/L Lymphocyte count &gt; Lower limit institutional normal Platelet count &gt; 80 x l09/L Serum creatinine &lt; 2.0 mg/dL Serum bilirubin &lt; 2 x upper limit institutional normal AST/ALT &lt; 2 x upper limit institutional normal 4 . Patients must ECOG performance status &lt; 2 ( ECOG criterion publish [ 46 ] ) 5 . Life expectancy &gt; 6 month . 6 . Age &gt; 18 year . 7 . Able willing give write informed consent participation trial ( see Section 12.2 ) 8 . Patients enrol adjuvant setting must receive standard curative therapy , e.g. , surgery , radiation . Alternatively , patient enter refuse standard curative therapy therapy clearly discuss treat physician fail another biologic therapy due toxicity . Exclusion Criteria Patients exclude study fulfill follow criterion : 1 . Serious illness , e.g. , serious infection require antibiotic . 2 . Previous bone marrow stem cell transplant . 3 . History immunodeficiency disease ( HIV ) autoimmune disease except vitiligo . 4 . Metastatic disease central nervous system . 5 . Other malignancy prior entry study . 6 . No radiation therapy , prior biological therapy surgery within 4 week prior first dose study agent . 7 . No prior chemotherapy prior vaccine immunotherapy . 8 . Concomitant treatment systemic corticosteroid great physiologic dos . Topical ( propose vaccination site ) inhalational steroid permit . ( See also Section 6.7 restrictions/recommendations 'Ancillary Therapy ' . ) 9 . Participation clinical trial involve another investigational agent within 4 week prior first dose study agent . 10 . Pregnancy lactation . 11 . Women childbearing potential use medically acceptable mean contraception . 12 . Patients known history inflammatory skin disorder ( e.g. , psoriasis , lupus ) may exacerbate Resiquimod . 13 . Psychiatric addictive disorder may compromise ability give informed consent . 14 . Lack availability patient immunological clinical followup assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Tumor</keyword>
	<keyword>NY-ESO-1 expression</keyword>
	<keyword>Tumors often express NY-ESO-1 .</keyword>
</DOC>